Guidelines : Inflammatory bowel disease

Detail

Condition :

Inflammatory bowel disease

Keywords :

IBD, CD, Chronic Bowel Disorder, inflammatory bowel disease, corticosteroid, 5-ASA, aminosalicylate, UC, ulcerative Colitis, prednisolone, mesalazine, crohns, lower GI symptoms, Crohn's, Crohn's disease, biologic, NICE, biosimilar, Sequential use of biologic medicines, TNF alpha inhibitor, Cytokine modulator, NICE, immunosuppressant, interleukin (IL)23 protein, DMARD, bDMARD, tsDMARD, Disease modulating, high cost immunomodulator, JAK inhibitor, Janus Kinase, Jakinib, Interleukin, IL 12/23, Immune checkpoint inhibitors, monoclonal antibodies, leukocyte integrin, sphingosine 1-phosphate (S1P) receptor modulator, anti-interleukin-23, anti-IL-23,

BNF Codes :

010500 - Chronic Bowel Disorders
010501 - Aminosalicylates
010503 - Drugs Affecting Immune Response

Committee Recommendations

Date

Committee Name

Narrative

Traffic Light Status

01 March 2023

Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated IBD immunomodulator pathway.

N/A

06 November 2019

Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey & North West Sussex Area Prescribing Committee recommend the use of an online toolkit to support prescribers when a patient presents with symptoms of IBD. The toolkit has been developed by the Royal College of Practitioners (RCGP) and Crohn's & Colitis UK. Follow this link to the toolkit https://www.rcgp.org.uk/ibd

N/A